Research programme: colloidal gold-based cancer therapeutics - CytImmune Sciences
Alternative Names: AuriCin; AuriTax; AuriTol; CYT-20000; CYT-21000; CYT-21001; CYT-21304; CYT-31000; CYT-41000; CYT-51000; CYT-61000; CYT-71000; PT-cAu-TNFLatest Information Update: 16 Jul 2016
At a glance
- Originator CytImmune Sciences
- Class Metals; Paclitaxels; Polyethylene glycols; Tumour necrosis factors
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV, Injection)
- 27 Feb 2013 OctoPlus has been acquired by Dr Reddys Laboratories
- 16 Apr 2008 Pharmacodynamics data from a preclinical trial presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)